

5 NOV 1962

OSMAEP/022.1

SUBJECT: Transfer of Funds for FY 63 Nuclear Weapons Effects Research (NWER) Program (W)

TO: AFSC (M&T Div) 1035750
Holling AFB
ATTN: RTW (Maj Hanson)
Wash 25 DC

1. Reference **SECRET** letter, Headquarters, DASA, OSMAEP/022.1, subject as above, 21 September 1962.
2. Referenced letter forwarded to the Air Force Special Weapons Center (AFSVC) Military Interdepartmental Purchase Request (MIPR) Number 120-63 for \$70,354.20. Funds were to be used to support subtasks 08.020 and 08.075 of the Nuclear Weapons Effects Research Program.
3. During informal conferences between representatives of AFSVC and project officers at this headquarters it was determined that subtask 08.075, 'Biologic Effects of Plutonium' is a part of the work being conducted by AFSVC and, therefore, should have been included in the biomedical program forwarded to them for management. Consequently, subtask 08.075 is assigned to the Air Force for management and \$60,000 will be forwarded by Amendment #1 to MIPR 120-63 for support of this research. This is the same amount of funds forwarded in FY 62.
4. Under the proposal AFSVC, or a contractor selected by them, will continue with their efforts to define the hazards to personnel of inhaled plutonium aerosol. The objectives of this subtask will be fulfilled if answers to the following questions can be found:
 - a. Is there a correlation between particle size and health hazards?

OFFICE SYMBOL	1	2	3	4	5	6	7
SURNAME OF COORDINATOR							
RAFTER	RANK OR GRADE:		SURNAME:		TYPESTAMP INITIALS		
INDICATE RECOMMENDED RETENTION PERIOD				PERMANENCE OR MEMORANDUM			
90 DAYS <input type="checkbox"/>		ONE YEAR <input type="checkbox"/>		TWO YEARS <input type="checkbox"/>		PERMANENT <input type="checkbox"/>	
						OTHER (SPECIFY)	

Declassified by DNA, Chief, ISTS

Robert L. ...
 DATE: 26 July 1994

~~CONFIDENTIAL~~

DASATP/928.1

SUBJECT: Transfer of Funds for FY 63 Nuclear Weapons Effects Research (NWER) Program

- b. What is the critical organ for inhaled plutonium?
- c. What is the rate of translocation of inhaled plutonium particles?
- d. What is the body burden following exposure to given concentrations of plutonium particles?
- e. What is the best method of determining the body burden?
- f. What appropriate countermeasures can be taken to:
 - (1) Decrease the possibility of plutonium inhalation and,
 - (2) Remove plutonium deposited within the body?
- g. Administrative paragraphs 4, 5, and 6 of referenced letter apply.

JOHN W. GANNON
Rear Admiral, USN
Deputy Chief

Copy furnished
AFNS-NS 1035751
AFNSC

M/R: Subtask 03.076, "Biologic Effects of Plutonium" was assigned to Air Force for management and \$60,000 was forwarded for support of research in FY 62. This subtask is a part of the approved FY 63 NWER program and another \$60,000 is being sent to SWC for continuation of the research.

CT: Charge funds to A-4 Biomedical, Task C, Subtask 03.076.

OFFICE SYMBOL	1 DASATP	2 DASAMD	3 DASART	4 DASACT	5 DASAAG	6	7
SURNAME OF COORDINATORS	<i>[Signature]</i>	<i>Gannon</i>	<i>[Signature]</i>	<i>[Signature]</i>	<i>[Signature]</i>	<i>[Signature]</i>	
DRAFTER	RANK OR GRADE: MAJ		SURNAME: TALBOTT		TYPISTS INITIALS: dpw ROOM NR: 2689 TEL: 56681		
INDICATE RECOMMENDED RETENT				OR MESSAGE typed 20 Oct 1962			
90 DAYS <input type="checkbox"/>		ONE YEAR <input type="checkbox"/>		TWO YEARS <input type="checkbox"/>		PERMANENT <input type="checkbox"/> OTHER (SPECIFY)	